Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02739386 · ClinicalTrials.gov registry record
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 370
- Enrollment target
NCT02739386 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 370 participants.
The verdict
NCT02739386 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 370 participants
- Enrollment target
Study Summary
The research questions to be addressed by this study are as follows: 1. What is the prevalence of ipilimumab use among adults with a history of autoimmune disease that received treatment with ipilimumab for advanced melanoma? 2. Do melanoma patients with a history of autoimmune disease experience complications that require hospitalization related to their underlying autoimmune disease following treatment with ipilimumab?
Interventions
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2017-03-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02739386
The ClinicalTrials.gov registry entry for NCT02739386 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipilimumab is the first listed.
NCT02739386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02739386 about?
NCT02739386 is a clinical study titled "Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases". The research questions to be addressed by this study are as follows: 1. What is the prevalence of ipilimumab use among adults with a history of autoimmune disease that received treatment with ipilimumab for advanced melanoma? 2. Do melanoma patients with a history of autoimmune disease experience c...
What is the current status of trial NCT02739386?
This trial is currently completed. The enrollment target is 370 participants. The study started on 2016-02-29. Estimated completion is 2017-03-30.
What interventions are being tested in trial NCT02739386?
The interventions under investigation include: Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02739386?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.